Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's Prime Minister ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...

Baltimore's school board joined districts across the country in suing drug makers over the skyrocketing costs of diabetes ...

Novo Nordisk’s collaboration with artificial intelligence startup Valo Health has focused on developing new drugs for cardiovascular ... including obesity and type 2 diabetes.

Denmark's Novo Nordisk on Wednesday announced an expansion of its collaboration with Valo Health to discover and develop ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

After coming to the US in 1982, it underwent several corporate changes until becoming Novo Nordisk in 1989. In addition to diabetes drugs, the company also makes drug treatments for wound healing ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Also Read: Novo Nordisk’s Older Generation Weight-Loss Drug Saxenda Associated With Decreased ... or ineffective for conditions such as type 2 diabetes, cardiovascular disease, and chronic ...